Poseida Therapeutics Inc (PSTX) Return on Equity ROE from the third quarter 2024 to third quarter 2023 and annually, average high and low, overall ranking from Sep 30 2024 to Sep 30 2023 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Poseida Therapeutics Inc   (NASDAQ: PSTX)

Poseida Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Poseida Therapeutics Inc in the third quarter 2024?
Poseida Therapeutics Inc recorded a cumulative net loss of $-61 million during 12 months ending in the third quarter 2024, resulting in a negative return on equity (ROE) of -72.26%.

Within the Biotechnology & Pharmaceuticals industry 78 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 3313, from total ROE ranking in the second quarter 2024 at 3374.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter
Y / Y Equity Change -29.48 % -55.05 % -46.31 % -44.72 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -61 -113 -109 -123 -132
Return On Equity (TTM) -72.26 % -121.01 % -97.36 % -94.9 % -87.41 %
PSTX's Total Ranking # 3313 # 3374 # 0 # 0 # 3443
Equity (TTM) in Millions 87 61 85 104 124
Seq. Equity Change 43.4 % -28.11 % -18.43 % -16.14 % -8.6 %
Seq. Net Income Change - - - - -

Back to PSTX Management Effectiveness >> PSTX's 5 Years Annual ROE >> Compare PSTX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 79
Sector # 519
Overall # 3313

Return On Equity Statistics
High Average Low
-17.12 %
-76.02 %
-121.01 %
(Jun 30 2023)   (Jun 30 2024)





PSTX Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions 104 188 156 262 0
Y / Y Equity Change -44.72 % 20.09 % -40.37 % - -
Net Income in Millions -123 -64 -125 -130 0
Y / Y Net Income Change - - - - -
Return On Equity -119.02 % -34.12 % -80 % -49.54 % -

Back to PSTX Management Effectiveness >> PSTX's 5 Years Annual ROE >> Compare PSTX ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PSTX's' Return on Equity at Yahoo Finance
PSTX's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PSTX's Competitors
Subscribers only: Roe for Poseida Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for PSTX's Customers




Companies with similar Return On Equity at Sep 30 2024, within Healthcare Sector ROE

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.